Thalia Therapeutics (LSE:THAT) has been granted a Patent in China covering the use of its lead candidate miRisten in acute myeloid leukaemia. The drug remains in a Phase 1 trial in the US, with top-line data targeted for the first half of 2027.

What was announced

On 29 September 2026 Thalia Therapeutics plc (LSE:THAT) said a new patent had been granted in China for miRisten (THAT-001), an anti-microRNA-126 therapeutic being developed initially for patients with acute myeloid leukaemia (AML), which the company describes as an aggressive blood cancer with significant unmet medical need.

According to the company, the patent covers the use of miRisten in the Chinese market. With this grant, protection for the programme extends across the US, the UK, Germany, France, Japan, European Patent Office countries and China.

The announcement does not give the patent number, the title of the patent, the scope of its claims or its expiry date. It contains no commercial terms, licensing arrangements or partnering information specific to China.

The patent estate and its origin

The miRisten patents are exclusively licensed from City of Hope, the US cancer treatment centre. They are held through Sanmirna Therapeutics Inc., which Thalia acquired in July 2026. City of Hope retains a financial interest in Thalia, according to the company's notes to editors.

Chief Executive Dr David Solomon said: "We are pleased to see further patent protection granted for miRisten in China. Strengthening the intellectual property supporting our lead clinical programme is an important part of its development as we work towards the next clinical milestones."

Clinical status and market context

miRisten is being evaluated in a Phase 1 dose-escalation trial at City of Hope in the US, in patients with relapsed or refractory AML. The company said the trial "continues to accrue patients" and that it is targeting top-line data in the first half of 2027. That timing is the company's target. The announcement does not disclose the number of patients enrolled, the dose levels tested or any interim safety or efficacy data.

The company cited an estimate that approximately 30,400 people will be newly diagnosed with AML in China in 2026. It also referred to a population-based study published in The Lancet Haematology in 2025, which estimated 43,275 new cases of acute leukaemia across all subtypes in China in 2019.

Thalia noted that the diagnosis figure does not reflect the smaller population that may be eligible for miRisten, since the drug is currently being developed for relapsed or refractory disease. The announcement gives no estimate of the size of that eligible group, and no clinical trial activity in China is mentioned.

Key points from the announcement:

  • Asset: miRisten (THAT-001), anti-microRNA-126 therapeutic
  • New grant: China, covering use in AML
  • Existing coverage: US, UK, Germany, France, Japan, EPO countries
  • Trial: Phase 1 dose escalation, relapsed/refractory AML, City of Hope
  • Company target: top-line data in H1 2027

Wider pipeline and what to watch next

Thalia describes itself as a developer of RNA-based therapeutics and delivery technologies in oncology and cardiovascular disease. Beyond miRisten, its pipeline includes THAT-002, a preclinical bispecific siRNA for atherosclerotic cardiovascular disease, and Nuvec (THAT-003), a proprietary delivery technology for RNA therapeutics.

The patent grant adds to the intellectual property around the company's lead asset but does not change its clinical stage. The next milestone the company has set out is the top-line Phase 1 readout in the first half of 2027. Updates on patient accrual, dose escalation and any further patent grants would provide more detail in the meantime. The announcement contains no financial information, cash position or funding update.